Insufficienza venosa cronica

Da Wikipedia, l'enciclopedia libera.
Avvertenza
Le informazioni riportate non sono consigli medici e potrebbero non essere accurate. I contenuti hanno solo fine illustrativo e non sostituiscono il parere medico: leggi le avvertenze.

L' insufficienza venosa cronica è una condizione caratterizzata da insufficiente ritorno venoso al cuore.

Può essere organica, se alla sua base vi sono alterazioni anatomiche delle vene, e funzionale se le vene, pur essendo integre, sono sottoposte ad un lavoro eccessivo e pertanto non sono in grado di garantire un ritorno venoso sufficiente.

Epidemiologia[modifica | modifica wikitesto]

Negli Stati Uniti ne è affetto sino al 5% della popolazione generale. Più colpito il sesso femminile in un rapporto di 2:1 rispetto al sesso maschile.

Eziologia[modifica | modifica wikitesto]

La perdita di elasticità della parete venosa e la distruzione delle valvole porta alla formazione di varici (dilatazioni patologiche permanenti delle vene). Le varici sono dovute alle gravidanze, all'obesità, alla sedentarietà, all'uso di anticoncezionali orali, o a patologie quali la trombosi venosa profonda. L'insorgenza di varici è spesso condizionata anche dalla familiarità o dal tipo di lavoro svolto.

Sintomatologia[modifica | modifica wikitesto]

Sugli arti inferiori si può rilevare la presenza di vene varicose o di teleangectasie e di distrofie cutanee che nei casi più gravi arrivano fino alle ulcere. Il paziente può avvertire pesantezza agli arti inferiori, gonfiore, parestesie, prurito, dolore di tipo crampiforme. Questi sintomi ovviamente peggiorano nella stagione calda.

Esami[modifica | modifica wikitesto]

L'anamnesi ed esame obiettivo permettono di formulare la diagnosi; l'ecocolor Doppler permette di valutare la morfologia e la funzione delle vene degli arti inferiori.

Terapia[modifica | modifica wikitesto]

Si devono correggere in generale in primo luogo le abitudini alimentari e lo stile di vita dell'individuo.

Poi può essere sempre utile l'utilizzo di calze elastiche e comunque la compressione della gamba.

Tra le terapie farmacologiche e fitoterapiche vengono comunemente usati preparati che contengono una serie di principi attivi di documentata efficacia; tra questi i più noti ed usati sono, spesso sotto forma di fitocomplessi, i seguenti principi attivi:

La vitis vinifera possiede documentate attività su:

Il Ginkgo biloba possiede documentate attività su:

L'ippocastano o haesculus hippocastanum possiede documentate attività su:

La rutina (Quercetin-3-O-rutinoside o Rutin o rutoside) possiede documentate attività su:

La amamedile o hamamelis virginiana possiede documentate attività su:

La diosmina possiede documentate attività su:

La luteina possiede documentate attività su:

L'esperidina possiede documentate attività su:

Note[modifica | modifica wikitesto]

  1. ^ M. Pirinççioğlu, G. Kızıl; M. Kızıl; G. Ozdemir; Z. Kanay; M. Aydın Ketani, Protective effect of Öküzgözü (Vitis vinifera L. cv.) grape juice against carbon tetrachloride induced oxidative stress in rats. in Food Funct, Mar 2012, DOI:10.1039/c2fo30024a, PMID 22434241.
  2. ^ D. Fraternale, R. De Bellis; C. Calcabrini; L. Potenza; L. Cucchiarini; U. Mancini; M. Dachà; D. Ricci, Aqueous extract from Vitis vinifera tendrils is able to enrich keratinocyte antioxidant defences. in Nat Prod Commun, vol. 6, nº 9, Sep 2011, pp. 1315-9, PMID 21941905.
  3. ^ A. Filip, D. Daicoviciu; S. Clichici; P. Bolfa; C. Catoi; I. Baldea; L. Bolojan; D. Olteanu; A. Muresan; ID. Postescu, The effects of grape seeds polyphenols on SKH-1 mice skin irradiated with multiple doses of UV-B. in J Photochem Photobiol B, vol. 105, nº 2, Nov 2011, pp. 133-42, DOI:10.1016/j.jphotobiol.2011.08.002, PMID 21925895.
  4. ^ AA. Hemmati, N. Aghel; I. Rashidi; A. Gholampur-Aghdami, Topical grape (Vitis vinifera) seed extract promotes repair of full thickness wound in rabbit. in Int Wound J, vol. 8, nº 5, Oct 2011, pp. 514-20, DOI:10.1111/j.1742-481X.2011.00833.x, PMID 21816000.
  5. ^ AF. Emiliano, LC. de Cavalho; V. da Silva Cristino Cordeiro; CA. da Costa; PB. de Oliveira; EF. Queiroz; DD. Col Moreira; GT. Boaventura; RS. de Moura; AC. Resende, Metabolic disorders and oxidative stress programming in offspring of rats fed a high-fat diet during lactation: effects of a vinifera grape skin (ACH09) extract. in J Cardiovasc Pharmacol, vol. 58, nº 3, Sep 2011, pp. 319-28, DOI:10.1097/FJC.0b013e3182244a51, PMID 21697730.
  6. ^ a b c d e J. Reuter, U. Wölfle; HC. Korting; C. Schempp, Which plant for which skin disease? Part 2: Dermatophytes, chronic venous insufficiency, photoprotection, actinic keratoses, vitiligo, hair loss, cosmetic indications. in J Dtsch Dermatol Ges, vol. 8, nº 11, Nov 2010, pp. 866-73, DOI:10.1111/j.1610-0387.2010.07472.x, PMID 20707877.
  7. ^ a b S. Chiummariello, F. De Gado; C. Monarca; M. Ruggiero; B. Carlesimo; N. Scuderi; C. Alfano, [Multicentric study on a topical compound with lymph-draining action in the treatment of the phlebostatic ulcer of the inferior limbs]. in G Chir, vol. 30, 11-12, pp. 497-501, PMID 20109380.
  8. ^ a b c A. Costantini, T. De Bernardi; A. Gotti, [Clinical and capillaroscopic evaluation of chronic uncomplicated venous insufficiency with procyanidins extracted from vitis vinifera]. in Minerva Cardioangiol, vol. 47, 1-2, pp. 39-46, PMID 10356940.
  9. ^ a b D. Zafirov, G. Bredy-Dobreva; V. Litchev; M. Papasova, Antiexudative and capillaritonic effects of procyanidines isolated from grape seeds (V. Vinifera). in Acta Physiol Pharmacol Bulg, vol. 16, nº 3, 1990, pp. 50-4, PMID 1714228.
  10. ^ YH. Mahadeswaraswamy, S. Nagaraju; KS. Girish; K. Kemparaju, Local tissue destruction and procoagulation properties of Echis carinatus venom: inhibition by Vitis vinifera seed methanol extract. in Phytother Res, vol. 22, nº 7, Jul 2008, pp. 963-9, DOI:10.1002/ptr.2462, PMID 18567054.
  11. ^ R. Maffei Facino, M. Carini; G. Aldini; E. Bombardelli; P. Morazzoni; R. Morelli, Free radicals scavenging action and anti-enzyme activities of procyanidines from Vitis vinifera. A mechanism for their capillary protective action. in Arzneimittelforschung, vol. 44, nº 5, maggio 1994, pp. 592-601, PMID 8024628.
  12. ^ YJ. Surh, KS. Chun; HH. Cha; SS. Han; YS. Keum; KK. Park; SS. Lee, Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-kappa B activation. in Mutat Res, 480-481, Sep 2001, pp. 243-68, PMID 11506818.
  13. ^ BS. Nayak, DD. Ramdath; JR. Marshall; GN. Isitor; M. Eversley; S. Xue; J. Shi, Wound-healing activity of the skin of the common grape (Vitis Vinifera) variant, Cabernet Sauvignon. in Phytother Res, vol. 24, nº 8, Aug 2010, pp. 1151-7, DOI:10.1002/ptr.2999, PMID 20066659.
  14. ^ M. Mi Jeong Sung, W. Davaatseren; SH. Kim; YS. Sung Kwang Park; . Kim; . Haeng Jeon Hur; . Myung Sunny Kim; . Kim; . Dae Young Kwon, Vitisin A suppresses LPS-induced NO production by inhibiting ERK, p38, and NF-kappaB activation in RAW 264.7 cells. in Int Immunopharmacol, vol. 9, nº 3, Mar 2009, pp. 319-23, DOI:10.1016/j.intimp.2008.12.005, PMID 19135555.
  15. ^ U. Cornelli, Treatment of Alzheimer's disease with a cholinesterase inhibitor combined with antioxidants. in Neurodegener Dis, vol. 7, 1-3, 2010, pp. 193-202, DOI:10.1159/000295663, PMID 20224285.
  16. ^ D. Parsad, R. Pandhi; A. Juneja, Effectiveness of oral Ginkgo biloba in treating limited, slowly spreading vitiligo. in Clin Exp Dermatol, vol. 28, nº 3, maggio 2003, pp. 285-7, PMID 12780716.
  17. ^ S. Pietri, JR. Séguin; P. d'Arbigny; K. Drieu; M. Culcasi, Ginkgo biloba extract (EGb 761) pretreatment limits free radical-induced oxidative stress in patients undergoing coronary bypass surgery. in Cardiovasc Drugs Ther, vol. 11, nº 2, Apr 1997, pp. 121-31, PMID 9140689.
  18. ^ I. Emerit, N. Oganesian; T. Sarkisian; R. Arutyunyan; A. Pogosian; K. Asrian; A. Levy; L. Cernjavski, Clastogenic factors in the plasma of Chernobyl accident recovery workers: anticlastogenic effect of Ginkgo biloba extract. in Radiat Res, vol. 144, nº 2, Nov 1995, pp. 198-205, PMID 7480646.
  19. ^ R. Arendt, [Acute pancreatitis--a Free radical disease. Decreasing mortality by sodium selenite (Na2SeO3) therapy. Discussion of the above named contribution by B. Kuklinski, M. Buchner, R. Schweder, R. Nagel]. in Z Gesamte Inn Med, vol. 47, nº 4, Apr 1992, pp. 163-4, PMID 1317623.
  20. ^ AV. Pokrovskiĭ, SV. Sapelkin; LA. Galaktionova; EE. Fedorov, [The assessment of medical therapy effectiveness of patients with lower limb chronic venous insufficiency: the results of prospective study with Ginkor Fort]. in Angiol Sosud Khir, vol. 11, nº 3, 2005, pp. 47-52, PMID 16439948.
  21. ^ MC. Misra, . Imlitemsu, Drug treatment of haemorrhoids. in Drugs, vol. 65, nº 11, 2005, pp. 1481-91, PMID 16134260.
  22. ^ E. Ernst, Herbal medications for common ailments in the elderly. in Drugs Aging, vol. 15, nº 6, Dec 1999, pp. 423-8, PMID 10641953.
  23. ^ F. Clostre, [Ginkgo biloba extract (EGb 761). State of knowledge in the dawn of the year 2000]. in Ann Pharm Fr, 57 Suppl 1, Jul 1999, pp. 1S8-88, PMID 10481350.
  24. ^ D. Janssens, C. Michiels; G. Guillaume; B. Cuisinier; Y. Louagie; J. Remacle, Increase in circulating endothelial cells in patients with primary chronic venous insufficiency: protective effect of Ginkor Fort in a randomized double-blind, placebo-controlled clinical trial. in J Cardiovasc Pharmacol, vol. 33, nº 1, Jan 1999, pp. 7-11, PMID 9890390.
  25. ^ L. Wang, T. Shen; CF. Zhou; JF. Yu; QX. Zhu, [Changes of nitric oxide after trichloroethylene irritation in hairless mice skin and protection of ginkgo biloba extract and vitamin E]. in Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi, vol. 27, nº 4, Apr 2009, pp. 207-10, PMID 19493483.
  26. ^ L. Biddlestone, AD. Corbett; S. Dolan, Oral administration of Ginkgo biloba extract, EGb-761 inhibits thermal hyperalgesia in rodent models of inflammatory and post-surgical pain. in Br J Pharmacol, vol. 151, nº 2, maggio 2007, pp. 285-91, DOI:10.1038/sj.bjp.0707220, PMID 17375081.
  27. ^ a b H. Lim, KH. Son; HW. Chang; SS. Kang; HP. Kim, Effects of anti-inflammatory biflavonoid, ginkgetin, on chronic skin inflammation. in Biol Pharm Bull, vol. 29, nº 5, maggio 2006, pp. 1046-9, PMID 16651744.
  28. ^ SY. Huang, C. Jeng; SC. Kao; JJ. Yu; DZ. Liu, Improved haemorrheological properties by Ginkgo biloba extract (Egb 761) in type 2 diabetes mellitus complicated with retinopathy. in Clin Nutr, vol. 23, nº 4, Aug 2004, pp. 615-21, DOI:10.1016/j.clnu.2003.10.010, PMID 15297098.
  29. ^ J. Zhang, S. Fu; S. Liu; T. Mao; R. Xiu, The therapeutic effect of Ginkgo biloba extract in SHR rats and its possible mechanisms based on cerebral microvascular flow and vasomotion. in Clin Hemorheol Microcirc, vol. 23, 2-4, 2000, pp. 133-8, PMID 11321432.
  30. ^ Y. Qiu, YC. Rui; TJ. Li; L. Zhang; PY. Yao, Inhibitory effect of extracts of Ginkgo biloba leaves on VEGF-induced hyperpermeability of bovine coronary endothelial cells in vitro. in Acta Pharmacol Sin, vol. 25, nº 10, Oct 2004, pp. 1306-11, PMID 15456532.
  31. ^ a b EY. Ryu, AJ. Park; SY. Park; SH. Park; HW. Eom; YH. Kim; G. Park; SJ. Lee, Inhibitory Effects of Ginkgo biloba Extract on Inflammatory Mediator Production by Porphyromonas gingivalis Lipopolysaccharide in Murine Macrophages via Nrf-2 Mediated Heme Oxygenase-1 Signaling Pathways. in Inflammation, Apr 2012, DOI:10.1007/s10753-012-9461-6, PMID 22476936.
  32. ^ AP. Rogerio, A. Sá-Nunes; LH. Faccioli, The activity of medicinal plants and secondary metabolites on eosinophilic inflammation. in Pharmacol Res, vol. 62, nº 4, Oct 2010, pp. 298-307, DOI:10.1016/j.phrs.2010.04.005, PMID 20450976.
  33. ^ S. Trompezinski, M. Bonneville; I. Pernet; A. Denis; D. Schmitt; J. Viac, Gingko biloba extract reduces VEGF and CXCL-8/IL-8 levels in keratinocytes with cumulative effect with epigallocatechin-3-gallate. in Arch Dermatol Res, vol. 302, nº 3, Apr 2010, pp. 183-9, DOI:10.1007/s00403-009-0979-x, PMID 19597830.
  34. ^ DD. Haines, B. Varga; I. Bak; B. Juhasz; FF. Mahmoud; H. Kalantari; R. Gesztelyi; I. Lekli; A. Czompa; A. Tosaki, Summative interaction between astaxanthin, Ginkgo biloba extract (EGb761) and vitamin C in suppression of respiratory inflammation: a comparison with ibuprofen. in Phytother Res, vol. 25, nº 1, Jan 2011, pp. 128-36, DOI:10.1002/ptr.3160, PMID 20632299.
  35. ^ I. Küçükkurt, S. Ince; H. Keleş; EK. Akkol; G. Avci; E. Yeşilada; E. Bacak, Beneficial effects of Aesculus hippocastanum L. seed extract on the body's own antioxidant defense system on subacute administration. in J Ethnopharmacol, vol. 129, nº 1, maggio 2010, pp. 18-22, DOI:10.1016/j.jep.2010.02.017, PMID 20219666.
  36. ^ CB. Methlie, J. Schjøtt, [Horse chestnut--remedy for chronic venous insufficiency]. in Tidsskr Nor Laegeforen, vol. 129, nº 5, Feb 2009, pp. 420-2, DOI:10.4045/tidsskr.09.33871, PMID 19247403.
  37. ^ a b c MR. Cesarone, G. Belcaro; MG. Grossi; L. Pellegrini; A. Ledda; G. Vinciguerra; A. Ricci; G. Gizzi; E. Ippolito; F. Fano; M. Dugall, LINFAVENIX: improvement of signs and symptoms of chronic venous insufficiency and microangiopathy. in Minerva Cardioangiol, vol. 56, 5 Suppl, Oct 2008, pp. 55-61, PMID 19597413.
  38. ^ a b A. Suter, S. Bommer; J. Rechner, Treatment of patients with venous insufficiency with fresh plant horse chestnut seed extract: a review of 5 clinical studies. in Adv Ther, vol. 23, nº 1, pp. 179-90, PMID 16644618.
  39. ^ S. Dickson, J. Gallagher; L. McIntyre; A. Suter; J. Tan, An open study to assess the safety and efficacy of Aesculus hippocastanum tablets (Aesculaforce 50mg) in the treatment of chronic venous insufficiency. in J Herb Pharmacother, vol. 4, nº 2, 2004, pp. 19-32, PMID 15364642.
  40. ^ MH. Pittler, E. Ernst, Horse chestnut seed extract for chronic venous insufficiency. in Cochrane Database Syst Rev, nº 1, 2006, pp. CD003230, DOI:10.1002/14651858.CD003230.pub3, PMID 16437450.
  41. ^ a b c d e M. Perrin, AA. Ramelet, Pharmacological treatment of primary chronic venous disease: rationale, results and unanswered questions. in Eur J Vasc Endovasc Surg, vol. 41, nº 1, Jan 2011, pp. 117-25, DOI:10.1016/j.ejvs.2010.09.025, PMID 21126890.
  42. ^ Aesculus hippocastanum (Horse chestnut). Monograph. in Altern Med Rev, vol. 14, nº 3, Sep 2009, pp. 278-83, PMID 19803552.
  43. ^ F. Wei, LY. Ma; WT. Jin; SC. Ma; GZ. Han; IA. Khan; RC. Lin, Antiinflammatory triterpenoid saponins from the seeds of Aesculus chinensis. in Chem Pharm Bull (Tokyo), vol. 52, nº 10, Oct 2004, pp. 1246-8, PMID 15467246.
  44. ^ CR. Sirtori, Aescin: pharmacology, pharmacokinetics and therapeutic profile. in Pharmacol Res, vol. 44, nº 3, Sep 2001, pp. 183-93, DOI:10.1006/phrs.2001.0847, PMID 11529685.
  45. ^ a b H. Matsuda, Y. Li; T. Murakami; K. Ninomiya; J. Yamahara; M. Yoshikawa, Effects of escins Ia, Ib, IIa, and IIb from horse chestnut, the seeds of Aesculus hippocastanum L., on acute inflammation in animals. in Biol Pharm Bull, vol. 20, nº 10, Oct 1997, pp. 1092-5, PMID 9353571.
  46. ^ JA. Wilkinson, AM. Brown, Horse Chestnut - Aesculus Hippocastanum: Potential Applications in Cosmetic Skin-care Products. in Int J Cosmet Sci, vol. 21, nº 6, Dec 1999, pp. 437-47, DOI:10.1046/j.1467-2494.1999.234192.x, PMID 18503457.
  47. ^ a b W. Xin, L. Zhang; F. Sun; N. Jiang; H. Fan; T. Wang; Z. Li; J. He; F. Fu, Escin exerts synergistic anti-inflammatory effects with low doses of glucocorticoids in vivo and in vitro. in Phytomedicine, vol. 18, nº 4, Feb 2011, pp. 272-7, DOI:10.1016/j.phymed.2010.08.013, PMID 20850956.
  48. ^ B. Ottillinger, K. Greeske, Rational therapy of chronic venous insufficiency--chances and limits of the therapeutic use of horse-chestnut seeds extract. in BMC Cardiovasc Disord, vol. 1, 2001, p. 5, PMID 11747472.
  49. ^ M. Montopoli, G. Froldi; MC. Comelli; M. Prosdocimi; L. Caparrotta, Aescin protection of human vascular endothelial cells exposed to cobalt chloride mimicked hypoxia and inflammatory stimuli. in Planta Med, vol. 73, nº 3, Mar 2007, pp. 285-8, DOI:10.1055/s-2007-967118, PMID 17310430.
  50. ^ G. Agati, G. Stefano; S. Biricolti; M. Tattini, Mesophyll distribution of 'antioxidant' flavonoid glycosides in Ligustrum vulgare leaves under contrasting sunlight irradiance. in Ann Bot, vol. 104, nº 5, Oct 2009, pp. 853-61, DOI:10.1093/aob/mcp177, PMID 19633310.
  51. ^ R. Acquaviva, R. Lanteri; G. Li Destri; R. Caltabiano; L. Vanella; S. Lanzafame; A. Di Cataldo; G. Li Volti; C. Di Giacomo, Beneficial effects of rutin and L-arginine coadministration in a rat model of liver ischemia-reperfusion injury. in Am J Physiol Gastrointest Liver Physiol, vol. 296, nº 3, Mar 2009, pp. G664-70, DOI:10.1152/ajpgi.90609.2008, PMID 19109403.
  52. ^ B. Marzani, M. Balage; A. Vénien; T. Astruc; I. Papet; D. Dardevet; L. Mosoni, Antioxidant supplementation restores defective leucine stimulation of protein synthesis in skeletal muscle from old rats. in J Nutr, vol. 138, nº 11, Nov 2008, pp. 2205-11, DOI:10.3945/jn.108.094029, PMID 18936220.
  53. ^ WK. Whang, HS. Park; I. Ham; M. Oh; H. Namkoong; HK. Kim; DW. Hwang; SY. Hur; TE. Kim; YG. Park; JR. Kim, Natural compounds,fraxin and chemicals structurally related to fraxin protect cells from oxidative stress. in Exp Mol Med, vol. 37, nº 5, Oct 2005, pp. 436-46, PMID 16264268.
  54. ^ L. de Franceschi, F. Turrini; M. Honczarenko; K. Ayi; A. Rivera; MD. Fleming; T. Law; F. Mannu; FA. Kuypers; A. Bast; WJ. van der Vijgh, In vivo reduction of erythrocyte oxidant stress in a murine model of beta-thalassemia. in Haematologica, vol. 89, nº 11, Nov 2004, pp. 1287-98, PMID 15531450.
  55. ^ a b JM. Cohen, EA. Akl; SR. Kahn, Pharmacologic and compression therapies for postthrombotic syndrome: a systematic review of randomized controlled trials. in Chest, vol. 141, nº 2, Feb 2012, pp. 308-20, DOI:10.1378/chest.11-1175, PMID 22315114.
  56. ^ SR. Kahn, How I treat postthrombotic syndrome. in Blood, vol. 114, nº 21, Nov 2009, pp. 4624-31, DOI:10.1182/blood-2009-07-199174, PMID 19741190.
  57. ^ IuM. Stoĭko, VG. Gudymovich, [Pathophysiological mechanisms of lower limb chronic venous insufficiency and possibility of its correction with Antistax]. in Angiol Sosud Khir, vol. 12, nº 3, 2006, pp. 77-82, PMID 17641618.
  58. ^ a b c d e f MR. Cesarone, G. Belcaro; P. Rohdewald; L. Pellegrini; A. Ledda; G. Vinciguerra; A. Ricci; G. Gizzi; E. Ippolito; F. Fano; M. Dugall, Improvement of diabetic microangiopathy with pycnogenol: A prospective, controlled study. in Angiology, vol. 57, nº 4, pp. 431-6, PMID 17022378.
  59. ^ MR. Cesarone, G. Belcaro; E. Ippolito; L. Pellegrini; A. Ledda; R. Luzzi; A. Ricci; M. Dugall; P. Bavera; M. Hosoi; S. Stuard, Clinical improvement in chronic venous insufficiency signs and symptoms with Venoruton (HR): an 8-month, open-registry, cost-efficacy study. in Panminerva Med, vol. 52, 2 Suppl 1, Jun 2010, pp. 43-8, PMID 20657534.
  60. ^ G. Belcaro, MR. Cesarone; A. Ledda; M. Cacchio; I. Ruffini; A. Ricci; E. Ippolito; A. Di Renzo; M. Dugall; M. Corsi; AR. Marino Santarelli, 5-Year control and treatment of edema and increased capillary filtration in venous hypertension and diabetic microangiopathy using O-(beta-hydroxyethyl)-rutosides: a prospective comparative clinical registry. in Angiology, 59 Suppl 1, pp. 14S-20S, DOI:10.1177/0003319707312683, PMID 18287163.
  61. ^ MS. Gohel, AH. Davies, Pharmacological agents in the treatment of venous disease: an update of the available evidence. in Curr Vasc Pharmacol, vol. 7, nº 3, Jul 2009, pp. 303-8, PMID 19601855.
  62. ^ CE. Quijano, E. Abalos, Conservative management of symptomatic and/or complicated haemorrhoids in pregnancy and the puerperium. in Cochrane Database Syst Rev, nº 3, 2005, pp. CD004077, DOI:10.1002/14651858.CD004077.pub2, PMID 16034920.
  63. ^ AA. Bamigboye, GJ. Hofmeyr, Interventions for leg edema and varicosities in pregnancy. What evidence? in Eur J Obstet Gynecol Reprod Biol, vol. 129, nº 1, Nov 2006, pp. 3-8, DOI:10.1016/j.ejogrb.2006.03.008, PMID 16678328.
  64. ^ H. Javed, MM. Khan; A. Ahmad; K. Vaibhav; ME. Ahmad; A. Khan; M. Ashafaq; F. Islam; MS. Siddiqui; MM. Safhi; F. Islam, Rutin prevents cognitive impairments by ameliorating oxidative stress and neuroinflammation in rat model of sporadic dementia of Alzheimer type. in Neuroscience, Mar 2012, DOI:10.1016/j.neuroscience.2012.02.046, PMID 22441036.
  65. ^ W. Arjumand, A. Seth; S. Sultana, Rutin attenuates cisplatin induced renal inflammation and apoptosis by reducing NFκB, TNF-α and caspase-3 expression in wistar rats. in Food Chem Toxicol, vol. 49, nº 9, Sep 2011, pp. 2013-21, DOI:10.1016/j.fct.2011.05.012, PMID 21605616.
  66. ^ M. Moshahid Khan, SS. Raza; H. Javed; A. Ahmad; A. Khan; F. Islam; MM. Safhi; F. Islam, Rutin Protects Dopaminergic Neurons from Oxidative Stress in an Animal Model of Parkinson's Disease. in Neurotox Res, Dec 2011, DOI:10.1007/s12640-011-9295-2, PMID 22194158.
  67. ^ M. Mitjans, V. Ugartondo; V. Martínez; S. Touriño; JL. Torres; MP. Vinardell, Role of galloylation and polymerization in cytoprotective effects of polyphenolic fractions against hydrogen peroxide insult. in J Agric Food Chem, vol. 59, nº 5, Mar 2011, pp. 2113-9, DOI:10.1021/jf1025532, PMID 21294572.
  68. ^ CA. Erdelmeier, J. Cinatl; H. Rabenau; HW. Doerr; A. Biber; E. Koch, Antiviral and antiphlogistic activities of Hamamelis virginiana bark. in Planta Med, vol. 62, nº 3, Jun 1996, pp. 241-5, DOI:10.1055/s-2006-957868, PMID 8693037.
  69. ^ D. MacKay, Hemorrhoids and varicose veins: a review of treatment options. in Altern Med Rev, vol. 6, nº 2, Apr 2001, pp. 126-40, PMID 11302778.
  70. ^ N. Jiang, W. Xin; T. Wang; L. Zhang; H. Fan; Y. Du; C. Li; F. Fu, Protective effect of aescin from the seeds of Aesculus hippocastanum on liver injury induced by endotoxin in mice. in Phytomedicine, vol. 18, nº 14, Nov 2011, pp. 1276-84, DOI:10.1016/j.phymed.2011.06.011, PMID 21802269.
  71. ^ S. Srinivasan, L. Pari, Ameliorative effect of diosmin, a citrus flavonoid against streptozotocin-nicotinamide generated oxidative stress induced diabetic rats. in Chem Biol Interact, vol. 195, nº 1, Jan 2012, pp. 43-51, DOI:10.1016/j.cbi.2011.10.003, PMID 22056647.
  72. ^ Y. Tanrikulu, K. Kismet; S. Serin Kilicoglu; E. Devrim; S. Erel; C. Sen Tanrikulu; S. Dinc; OH. Edebal; E. Erdemli; MA. Akkus, Diosmin ameliorates intestinal injury induced by hepatic ischemia reperfusion in rats. in Bratisl Lek Listy, vol. 112, nº 10, 2011, pp. 545-51, PMID 21954537.
  73. ^ a b c d O. Firuzi, R. Miri; M. Tavakkoli; L. Saso, Antioxidant therapy: current status and future prospects. in Curr Med Chem, vol. 18, nº 25, 2011, pp. 3871-88, PMID 21824100.
  74. ^ B. Manuel y Keenoy, J. Vertommen; I. De Leeuw, The effect of flavonoid treatment on the glycation and antioxidant status in Type 1 diabetic patients. in Diabetes Nutr Metab, vol. 12, nº 4, Aug 1999, pp. 256-63, PMID 10782751.
  75. ^ A. Unlü, N. Sucu; L. Tamer; B. Coskun; G. Yücebilgiç; B. Ercan; A. Gül; M. Dikmengil; U. Atik, Effects of Daflon on oxidative stress induced by hindlimb ischemia/reperfusion. in Pharmacol Res, vol. 48, nº 1, Jul 2003, pp. 11-5, PMID 12770509.
  76. ^ E. Rapavi, I. Kocsis; E. Fehér; K. Szentmihályi; A. Lugasi; E. Székely; A. Blázovics, The effect of citrus flavonoids on the redox state of alimentary-induced fatty liver in rats. in Nat Prod Res, vol. 21, nº 3, Mar 2007, pp. 274-81, DOI:10.1080/14786410500518545, PMID 17365719.
  77. ^ ZV. Maksimović, M. Maksimović; D. Jadranin; I. Kuzmanović; O. Andonović, Medicamentous treatment of chronic venous insufficiency using semisynthetic diosmin--a prospective study. in Acta Chir Iugosl, vol. 55, nº 4, 2008, pp. 53-9, PMID 19245142.
  78. ^ a b MR. Cesarone, G. Belcaro; P. Rohdewald; L. Pellegrini; A. Ledda; G. Vinciguerra; A. Ricci; G. Gizzi; E. Ippolito; F. Fano; M. Dugall, Comparison of Pycnogenol and Daflon in treating chronic venous insufficiency: a prospective, controlled study. in Clin Appl Thromb Hemost, vol. 12, nº 2, Apr 2006, pp. 205-12, PMID 16708123.
  79. ^ a b F. Di Pierro, G. Spinelli; G. Monsù; G. Alvisi; G. Bacci; C. Baiocchi; M. Buratta; A. Martinoli; F. Vitali; C. Agrifoglio; F. Gennaioli, Clinical effectiveness of a highly standardized and bioavailable mixture of flavonoids and triterpenes in the management of acute hemorroidal crisis. in Acta Biomed, vol. 82, nº 1, Apr 2011, pp. 35-40, PMID 22069954.
  80. ^ S. Panpimanmas, S. Sithipongsri; C. Sukdanon; C. Manmee, Experimental comparative study of the efficacy and side effects of Cissus quadrangularis L. (Vitaceae) to Daflon (Servier) and placebo in the treatment of acute hemorrhoids. in J Med Assoc Thai, vol. 93, nº 12, Dec 2010, pp. 1360-7, PMID 21344797.
  81. ^ L. Pascarella, D. Lulic; AH. Penn; T. Alsaigh; J. Lee; H. Shin; V. Kapur; JJ. Bergan; GW. Schmid-Schönbein, Mechanisms in experimental venous valve failure and their modification by Daflon 500 mg. in Eur J Vasc Endovasc Surg, vol. 35, nº 1, Jan 2008, pp. 102-10, DOI:10.1016/j.ejvs.2007.08.011, PMID 17890112.
  82. ^ AA. Ramelet, Daflon 500 mg: symptoms and edema clinical update. in Angiology, 56 Suppl 1, pp. S25-32, PMID 16193223.
  83. ^ P. Galley, M. Thiollet, A double-blind, placebo-controlled trial of a new veno-active flavonoid fraction (S 5682) in the treatment of symptomatic capillary fragility. in Int Angiol, vol. 12, nº 1, Mar 1993, pp. 69-72, PMID 8376915.
  84. ^ T. Godfraind, Effect of a flavonoid preparation (S 5682) on experimental capillary permeability increase in rat paw and rabbit skin. in Int Angiol, vol. 7, 2 Suppl, pp. 17-9, PMID 3183452.
  85. ^ A. Sezer, U. Usta; Z. Kocak; MA. Yagci, The effect of a flavonoid fractions diosmin + hesperidin on radiation-induced acute proctitis in a rat model. in J Cancer Res Ther, vol. 7, nº 2, pp. 152-6, DOI:10.4103/0973-1482.82927, PMID 21768702.
  86. ^ J. Rovenský, M. Stancíková; E. Rovenská; S. Stvrtina; V. Stvrtinová; K. Svík, Treatment of rat adjuvant arthritis with flavonoid (Detralex), methotrexate, and their combination. in Ann N Y Acad Sci, vol. 1173, Sep 2009, pp. 798-804, DOI:10.1111/j.1749-6632.2009.04618.x, PMID 19758231.
  87. ^ O. Benavente-García, J. Castillo, Update on uses and properties of citrus flavonoids: new findings in anticancer, cardiovascular, and anti-inflammatory activity. in J Agric Food Chem, vol. 56, nº 15, Aug 2008, pp. 6185-205, DOI:10.1021/jf8006568, PMID 18593176.
  88. ^ J. Rovenský, K. Svík; E. Rovenská; V. Stvrtinová; M. Stancíková, Effects of purified micronized flavonoid fraction (Detralex) on prophylactic treatment of adjuvant arthritis with methotrexate in rats. in Isr Med Assoc J, vol. 10, nº 5, maggio 2008, pp. 377-80, PMID 18605365.
  89. ^ JJ. Bergan, Chronic venous insufficiency and the therapeutic effects of Daflon 500 mg. in Angiology, 56 Suppl 1, pp. S21-4, PMID 16193222.
  90. ^ Y. Ozawa, M. Sasaki; N. Takahashi; M. Kamoshita; S. Miyake; K. Tsubota, Neuroprotective effects of lutein in the retina. in Curr Pharm Des, vol. 18, nº 1, 2012, pp. 51-6, PMID 22211688.
  91. ^ S. Gao, T. Qin; Z. Liu; MA. Caceres; CF. Ronchi; CY. Chen; KJ. Yeum; A. Taylor; JB. Blumberg; Y. Liu; F. Shang, Lutein and zeaxanthin supplementation reduces H2O2-induced oxidative damage in human lens epithelial cells. in Mol Vis, vol. 17, 2011, pp. 3180-90, PMID 22194644.
  92. ^ a b Y. Kim, JH. Seo; H. Kim, β-Carotene and lutein inhibit hydrogen peroxide-induced activation of NF-κB and IL-8 expression in gastric epithelial AGS cells. in J Nutr Sci Vitaminol (Tokyo), vol. 57, nº 3, 2011, pp. 216-23, PMID 21908944.
  93. ^ a b JA. Evans, EJ. Johnson, The role of phytonutrients in skin health. in Nutrients, vol. 2, nº 8, Aug 2010, pp. 903-28, DOI:10.3390/nu2080903, PMID 22254062.
  94. ^ SY. Li, AC. Lo, Lutein Protects RGC-5 Cells Against Hypoxia and Oxidative Stress. in Int J Mol Sci, vol. 11, nº 5, 2010, pp. 2109-17, DOI:10.3390/ijms11052109, PMID 20559505.
  95. ^ KH. Costenbader, JH. Kang; EW. Karlson, Antioxidant intake and risks of rheumatoid arthritis and systemic lupus erythematosus in women. in Am J Epidemiol, vol. 172, nº 2, Jul 2010, pp. 205-16, DOI:10.1093/aje/kwq089, PMID 20534819.
  96. ^ B. Lambert, M. Lessard, Massive ovarian edema in a twin pregnancy. in Can J Surg, vol. 30, nº 1, Jan 1987, pp. 40-1, PMID 3815179.
  97. ^ SB. Vasquez, JF. Sotos; MH. Kim, Massive edema of the ovary and virilization. in Obstet Gynecol, vol. 59, 6 Suppl, Jun 1982, pp. 95S-9S, PMID 6283445.
  98. ^ Y. Yasuda, Y. Fujita; T. Musha; H. Tanaka; S. Shiokawa; K. Nakamatsu; S. Mori; T. Matsuo; Y. Nakamura, Expression of erythropoietin in human female reproductive organs. in Ital J Anat Embryol, vol. 106, 2 Suppl 2, 2001, pp. 215-22, PMID 11732580.
  99. ^ SR. Soares, R. Gómez; C. Simón; JA. García-Velasco; A. Pellicer, Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome. in Hum Reprod Update, vol. 14, nº 4, pp. 321-33, DOI:10.1093/humupd/dmn008, PMID 18385260.
  100. ^ G. Riccioni, L. Speranza; M. Pesce; S. Cusenza; N. D'Orazio; MJ. Glade, Novel phytonutrient contributors to antioxidant protection against cardiovascular disease. in Nutrition, Apr 2012, DOI:10.1016/j.nut.2011.11.028, PMID 22480801.
  101. ^ M. Rydén, P. Garvin; M. Kristenson; P. Leanderson; J. Ernerudh; L. Jonasson, Provitamin A carotenoids are independently associated with matrix metalloproteinase-9 in plasma samples from a general population. in J Intern Med, Apr 2012, DOI:10.1111/j.1365-2796.2012.2534.x, PMID 22486775.
  102. ^ R. Graydon, RE. Hogg; U. Chakravarthy; IS. Young; JV. Woodside, The effect of lutein- and zeaxanthin-rich foods v. supplements on macular pigment level and serological markers of endothelial activation, inflammation and oxidation: pilot studies in healthy volunteers. in Br J Nutr, Feb 2012, pp. 1-9, DOI:10.1017/S0007114511005599, PMID 22313522.
  103. ^ RR. He, B. Tsoi; F. Lan; N. Yao; XS. Yao; H. Kurihara, Antioxidant properties of lutein contribute to the protection against lipopolysaccharide-induced uveitis in mice. in Chin Med, vol. 6, nº 1, 2011, p. 38, DOI:10.1186/1749-8546-6-38, PMID 22040935.
  104. ^ a b N. Nandakumar, MP. Balasubramanian, Hesperidin protects renal and hepatic tissues against free radical-mediated oxidative stress during DMBA-induced experimental breast cancer. in J Environ Pathol Toxicol Oncol, vol. 30, nº 4, 2011, pp. 283-300, PMID 22181978.
  105. ^ a b c ST. Ahmad, W. Arjumand; S. Nafees; A. Seth; N. Ali; S. Rashid; S. Sultana, Hesperidin alleviates acetaminophen induced toxicity in Wistar rats by abrogation of oxidative stress, apoptosis and inflammation. in Toxicol Lett, vol. 208, nº 2, Jan 2012, pp. 149-61, DOI:10.1016/j.toxlet.2011.10.023, PMID 22093918.
  106. ^ a b A. Melchini, S. Catania; R. Stancanelli; S. Tommasini; C. Costa, Interaction of a functionalized complex of the flavonoid hesperetin with the AhR pathway and CYP1A1 expression: involvement in its protective effects against benzo[a]pyrene-induced oxidative stress in human skin. in Cell Biol Toxicol, vol. 27, nº 5, Oct 2011, pp. 371-9, DOI:10.1007/s10565-011-9194-6, PMID 21720915.
  107. ^ a b PP. Trivedi, S. Kushwaha; DN. Tripathi; GB. Jena, Cardioprotective effects of hesperetin against doxorubicin-induced oxidative stress and DNA damage in rat. in Cardiovasc Toxicol, vol. 11, nº 3, Sep 2011, pp. 215-25, DOI:10.1007/s12012-011-9114-2, PMID 21553131.
  108. ^ a b c d A. Petrova, LM. Davids; F. Rautenbach; JL. Marnewick, Photoprotection by honeybush extracts, hesperidin and mangiferin against UVB-induced skin damage in SKH-1 mice. in J Photochem Photobiol B, vol. 103, nº 2, maggio 2011, pp. 126-39, DOI:10.1016/j.jphotobiol.2011.02.020, PMID 21435898.
  109. ^ M. Jain, HS. Parmar, Evaluation of antioxidative and anti-inflammatory potential of hesperidin and naringin on the rat air pouch model of inflammation. in Inflamm Res, vol. 60, nº 5, maggio 2011, pp. 483-91, DOI:10.1007/s00011-010-0295-0, PMID 21181230.
  110. ^ SV. Sapelkin, [Edema as a measure for severity of chronic venous insufficiency and efficacy of its treatment]. in Angiol Sosud Khir, vol. 14, nº 3, 2008, pp. 79-81, PMID 19791434.
  111. ^ a b GR. Aguilar Peralta, J. Arévalo Gardoqui; FJ. Llamas Macías; VH. Navarro Ceja; SA. Mendoza Cisneros; CG. Martínez Macías, Clinical and capillaroscopic evaluation in the treatment of chronic venous insufficiency with Ruscus aculeatus, hesperidin methylchalcone and ascorbic acid in venous insufficiency treatment of ambulatory patients. in Int Angiol, vol. 26, nº 4, Dec 2007, pp. 378-84, PMID 18091707.
  112. ^ H. Takumi, R. Mukai; S. Ishiduka; T. Kometani; J. Terao, Tissue distribution of hesperetin in rats after a dietary intake. in Biosci Biotechnol Biochem, vol. 75, nº 8, 2011, pp. 1608-10, PMID 21821945.
  113. ^ RE. LEE, The unique role of ascorbic acid in peripheral vascular physiology as compared with rutin and hesperidin: a micromanipulative study. in J Nutr, vol. 72, Oct 1960, pp. 203-9, PMID 13760269.
  114. ^ E. Bouskela, FZ. Cyrino; L. Lerond, Effects of oral administration of different doses of purified micronized flavonoid fraction on microvascular reactivity after ischaemia/reperfusion in the hamster cheek pouch. in Br J Pharmacol, vol. 122, nº 8, Dec 1997, pp. 1611-6, DOI:10.1038/sj.bjp.0701554, PMID 9422805.
  115. ^ YR. Lee, JH. Jung; HS. Kim, Hesperidin partially restores impaired immune and nutritional function in irradiated mice. in J Med Food, vol. 14, nº 5, maggio 2011, pp. 475-82, DOI:10.1089/jmf.2010.1269, PMID 21434774.
  116. ^ C. Gandhi, A. Upaganalawar; R. Balaraman, Protection against in vivo focal myocardial ischemia/reperfusion injury-induced arrhythmias and apoptosis by hesperidin. in Free Radic Res, vol. 43, nº 9, Sep 2009, pp. 817-27, DOI:10.1080/10715760903071656, PMID 19579067.
  117. ^ K. Vafeiadou, D. Vauzour; HY. Lee; A. Rodriguez-Mateos; RJ. Williams; JP. Spencer, The citrus flavanone naringenin inhibits inflammatory signalling in glial cells and protects against neuroinflammatory injury. in Arch Biochem Biophys, vol. 484, nº 1, Apr 2009, pp. 100-9, DOI:10.1016/j.abb.2009.01.016, PMID 19467635.

Bibliografia[modifica | modifica wikitesto]

  • Research Laboratories Merck, The Merck Manual quinta edizione, Milano, Springer-Verlag, 2008, ISBN 978-88-470-0707-9.

Voci correlate[modifica | modifica wikitesto]

Medicina Portale Medicina: accedi alle voci di Wikipedia che trattano di Medicina